Tempest Therapeutics (TPST)’ PPARalpha inhibitor, a treatment of hepatocellular carcinoma, received FDA orphan designation, according to a post on the agency’s site.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPST:
- Tempest Therapeutics Reports Q3 2024 Financial Results
- Tempest Therapeutics price target lowered to $5 from $8 at Piper Sandler
- Tempest Therapeutics reports Q3 EPS (41c), consensus (36c)
- Tempest receives FDA study may proceed for Phase 3 trial of amezalpat
- Tempest Therpeutics options imply 22.5% move in share price post-earnings